Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
NCT01730339
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Subjects must have hypertrophic (raised) breast scars from previous surgery
- Subjects must be healthy
- Currently pregnant or pregnant during the 6 months, prior to inclusion in the study or
breast-feeding.
- Presence of history of breast cancer
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Irvine, California
- La Jolla, California
- La Jolla, California
- Walnut Creek, California
- Walnut Creek, California
- Walnut Creek, California
- Whittier, California
- Whittier, California
- Boca Raton, Florida
- Coral Gables, Florida
- Lake Worth, Florida
- Miami, Florida
- Tampa, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Conyers, Georgia
- Jonesboro, Georgia
- Chicago, Illinois
- Chicago, Illinois
- Saint Louis, Missouri
- St. Louis, Missouri
- Garden City, New York
- Manhasset, New York
- New York, New York
- Huntersville, North Carolina
- Tualatin, Oregon
- Tualatin, Oregon
- Tualatin, Oregon
- Bala Cynwyd, Pennsylvania
- Rapid City, South Dakota
- Rapid City, South Dakota
- Sugar Land, Texas
- Sugar Land, Texas
- Norfolk, Virginia
- Kassel, Hessen
- Budapest,
- Barcelona,
- Madrid,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery | |||
Official Title ICMJE | A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring | |||
Brief Summary | The study will compare how well PF-06473871 works versus placebo in reducing skin scarring after scar revision surgery of existing breast scars. The study will also evaluate the safety of PF-06473871 in healthy adult subjects. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Masking: Double (Participant, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | Reduction of Hypertrophic Skin Scarring | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 103 | |||
Original Estimated Enrollment ICMJE | 100 | |||
Actual Study Completion Date ICMJE | October 2014 | |||
Actual Primary Completion Date | October 2014 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 55 Years (Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Germany, Hungary, Spain, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT01730339 | |||
Other Study ID Numbers ICMJE | B5301001 2012-004355-37 ( EudraCT Number ) | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2016 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |